NCT06357559

Brief Summary

To Analyze the Ability of Optical Coherence Tomography Angiography ( OCT-A ) to detect the presence of myopic Choroidal Neovascularization and to describe the structural features of Myopic CNV..

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Apr 2024

Shorter than P25 for all trials

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 11, 2024

Completed
1 month until next milestone

First Posted

Study publicly available on registry

April 10, 2024

Completed
20 days until next milestone

Study Start

First participant enrolled

April 30, 2024

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 15, 2024

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2024

Completed
Last Updated

April 10, 2024

Status Verified

April 1, 2024

Enrollment Period

5 months

First QC Date

March 11, 2024

Last Update Submit

April 4, 2024

Conditions

Myopic Choroidal Neovascularisation

Outcome Measures

Primary Outcomes (1)

  • Describing the Choroidal Neovascularization in High Myopic Patients diagnosed by OCTA

    Describing the Choroidal Neovascularization in High Myopic Patients diagnosed by OCTA Regarding its Activity ..

    1 year

Interventions

OCTADEVICE

Optical Coherence Tomography Angiography

Eligibility Criteria

Age10 Years - 75 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with High Myopia ( Refractive Error \> -6D or Axial Length \> 26,5 mm ) with Fundoscopic Changes Consistent with CNVM.

You may qualify if:

  • All Patients with High Myopia ( \> -6 D or Axial Length \> 26.5 mm ) with Fundoscopic Changes Consistent with CNVM , with Clear Media are Subjected to OCTA

You may not qualify if:

  • Patients with Treated CNVs , or with other Causes of CNVs including :
  • Neovascular AMD , Idiopathic CNV , Traumatic , Inflammatory , Neoplastic , Degenerative ..

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Ohno-Matsui K, Ikuno Y, Lai TYY, Gemmy Cheung CM. Diagnosis and treatment guideline for myopic choroidal neovascularization due to pathologic myopia. Prog Retin Eye Res. 2018 Mar;63:92-106. doi: 10.1016/j.preteyeres.2017.10.005. Epub 2017 Oct 28.

    PMID: 29111299BACKGROUND

Central Study Contacts

Ahmed Hamdy

CONTACT

01287307536fcb9976@Gmail.com

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Dr.

Study Record Dates

First Submitted

March 11, 2024

First Posted

April 10, 2024

Study Start

April 30, 2024

Primary Completion

September 15, 2024

Study Completion

December 1, 2024

Last Updated

April 10, 2024

Record last verified: 2024-04